Yolanda Hanna, Lohnoo Tassanee, Rujirawat Thidarat, Yingyong Wanta, Kumsang Yothin, Sae-Chew Pattarana, Payattikul Penpan, Krajaejun Theerapong
Program in Translational Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Department of Parasitology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia.
J Fungi (Basel). 2022 Oct 24;8(11):1116. doi: 10.3390/jof8111116.
The orphan but highly virulent pathogen causes pythiosis in humans and animals. Surgery is a primary treatment aiming to cure but trading off losing affected organs. Antimicrobial drugs show limited efficacy in treating pythiosis. Alternative drugs effective against the pathogen are needed. In-house drug susceptibility tests (i.e., broth dilution, disc diffusion, and radial growth assays) have been established, some of which adapted the standard protocols (i.e., CLSI M38-A2 and CLSI M51) designed for fungi. Hyphal plug, hyphal suspension, and zoospore are inocula commonly used in the drug susceptibility assessment for . A side-by-side comparison demonstrated that each method had advantages and limitations. Minimum inhibitory and cidal concentrations of a drug varied depending on the selected method. Material availability, user experience, and organism and drug quantities determined which susceptibility assay should be used. We employed the hyphal plug and a combination of broth dilution and radial growth methods to screen and validate the anti- activities of several previously reported chemicals, including potassium iodide, triamcinolone acetonide, dimethyl sulfoxide, and ethanol, in which data on their anti- efficacy are limited. We tested each chemical against 29 genetically diverse isolates of . These chemicals possessed direct antimicrobial effects on the growth of the pathogen in a dose- and time-dependent manner, suggesting their potential application in pythiosis treatment. Future attempts should focus on standardizing these drug susceptibility methods, such as determining susceptibility/resistant breakpoints, so healthcare workers can confidently interpret a result and select an effective drug against .
这种罕见但毒性极强的病原体可导致人和动物发生芽生菌病。手术是主要的治疗手段,旨在治愈疾病,但要权衡切除受影响器官的代价。抗菌药物在治疗芽生菌病方面疗效有限。因此需要有效的替代药物来对抗这种病原体。已建立了内部药敏试验(即肉汤稀释法、纸片扩散法和径向生长试验),其中一些试验采用了针对真菌设计的标准方案(即CLSI M38 - A2和CLSI M51)。菌丝块、菌丝悬液和游动孢子是芽生菌病药敏评估中常用的接种物。并列比较表明,每种方法都有其优缺点。一种药物的最低抑菌浓度和杀菌浓度因所选方法而异。材料的可用性、用户经验以及生物体和药物的用量决定了应使用哪种药敏试验。我们采用菌丝块以及肉汤稀释法和径向生长法相结合的方式,对几种先前报道的化学物质(包括碘化钾、曲安奈德、二甲基亚砜和乙醇)的抗芽生菌病活性进行了筛选和验证,目前关于它们抗芽生菌病疗效的数据有限。我们针对29株基因多样的芽生菌分离株对每种化学物质进行了测试。这些化学物质对病原体的生长具有剂量和时间依赖性的直接抗菌作用,表明它们在芽生菌病治疗中具有潜在应用价值。未来的研究应致力于使这些药敏方法标准化,例如确定药敏/耐药断点,以便医护人员能够自信地解读结果并选择有效的抗芽生菌病药物。